Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Madrigal Pharmaceuticals Inc

MDGL ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Large Cap Analyst: BUY

Last Close

$507.56

▲ +0.04%

Market Cap $11.73B · Vol 65.37K

Key Metrics

P/E Ratio

N/A

FWD: 261.17

Market Cap

$11.73B

Large Cap

Div Yield

N/A

EPS Growth

+50.66%

YoY

RSI (14)

39.40

Momentum

Beta

-0.99

vs Market

52W High

$614.29

17.37% below

52W Low

$354.56

43.15% above

Volume

65.37K

Avg 105.65K

P/B

22.07

Price-to-book

ROE

-42.49%

Return on equity

Free Float

94.11%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Madrigal Pharmaceuticals Inc (MDGL) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MDGL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.49%

-5.46%

-5.99%

+9.22%

YTD

-12.84%

+36.67%

+191.42%

+498.11%

Financials & Valuation

TTM · Annual

Total Revenue	$958.40M
Net Income	$-288,284,000.00
Revenue Growth (YoY)	+71.17%
Gross Margin	94.14%
Operating Margin	-31.31%
Net Profit Margin	-30.08%
ROE	-42.49%
ROA · ROIC	-25.05% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	261.17
PEG Ratio	N/A
P/S	13.63
P/B	22.07
P/FCF	N/A
EPS Growth	+50.66%
Outstanding Shares	23.10M

Technical Indicators

50-Day SMA	$518.23
200-Day SMA	$511.28
RSI (14)	39.40
Beta	-0.99
52-Week High	$614.29
52-Week Low	$354.56

Volume Today	65.37K
Avg Daily Volume (30D)	105.65K
Relative Volume	0.62x
Volatility (10D)	44.07
Volatility (30D)	49.99
Free Float	94.11%

Analyst Consensus

BUY

Current Price $507.56

Mean Target $678.18

52W Low$354.56 52W High$614.29

Current

Target

$354.56 $614.29

Current Analyst target

+33.62% upside potential · 17 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SNKQ42

ISINUS5588681057

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 2, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).